Study identifies alternate cysteine-production route in mammalian cells

Cancer treatments often depend on overwhelming tumor cells with damage or stress, while cancer cells can survive through protective metabolic systems. This study supplies a previously unrecognized candidate mechanism for examining that resilience: cysteine production that does not rely on the two reductase systems previously considered indispensable. A future treatment approach would need to distinguish tumor use of the pathway from its role in healthy cells, but the result gives researchers a defined chemical reaction to test rather than only a general hypothesis about resistance.

Cysteine is a central cellular resource because it contributes to proteins, damage-control systems, and disulfide bonds that support protein structure. The established view described in the source was that cells needed at least one functioning disulfide reductase system to turn cystine, an oxidized form of cysteine, into cysteine. The newly reported route changes that model by showing a fallback reaction based on carbon-sulfur bond cleavage. Schmidt suggested that the mechanism may have evolved as protection from electrophilic toxins, but that evolutionary explanation remains a proposed interpretation rather than a demonstrated history. The study involved researchers and trainees at Montana State University and collaborating institutions, including the Hungarian National Institute of Oncology.

The first clue appeared in 2014, when genetically engineered mice survived despite the apparent absence of a known cystine-to-cysteine conversion mechanism. The team then spent seven more years identifying how cells maintained cysteine supply, according to the source. Important uncertainties remain: the report does not establish which cancers use this pathway, whether it drives resistance in a particular treatment setting, or whether it can be inhibited selectively enough to avoid harming healthy cells that may rely on the same backup system.